BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Interest Expense on Debt & Bank Loans by Year
Interest Expense on Debt & Bank Loans ($M) ($M)
BeOne Medicines Interest Expense on Debt & Bank Loans: $50M in FY2025, up 6.6% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
50
Period ended Dec 31, 2025
Change on a year earlier
+6.6%
46.9 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Debt Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Interest Expense on Debt & Bank Loans ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50 | +6.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 46.9 | +125.5% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 20.8 | -4.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 21.7 | -25.9% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 29.3 | +60.1% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 18.3 | +20.4% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 15.2 | +15.2% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 13.2 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Interest Expense on Debt & Bank Loans ($M), annual FY2018–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/interest-exp-debt
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.